The US Food and Drug Administration (FDA) has granted expanded 510(k) marketing clearance for Nanotherapeutics’ bone void filler product, NanoFUSE demineralised bone matrix (DBM), for use in spinal fusion surgery.

The bone void filler has received FDA clearance specifically for use with autograft, where a bone is transplanted from a patient’s own body, as a bone graft extender in the posterolateral spine.

NanoFUSE DBM is a new composite allograft, or human tissue graft, designed to improve surgical handling performance, graft stability and osteoproductivity.

The product features bioactive glass that facilitates operative site graft containment through rapid bone bonding and activation of cellular osteogenesis (bone formation).

“NanoFUSE DBM is a new composite allograft…designed to improve surgical handling performance, graft stability and osteoproductivity.”

According to Nanotherapeutics, the combined properties of DBM and bioactive glass create a highly favourable environment for bone fusion, as it remodels into the recipient’s skeletal system.

Surgeons will place the NanoFUSE DBM in bony voids or gaps within the skeletal system that are not intrinsic to the stability of the structure.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The bony voids or gaps may be surgically created osseous defects or the result of prior traumatic injury.

NanoFUSE DBM is formulated so that it reconstitutes into a paste upon addition of a sterile fluid, such as saline, water for injection and/or autologous blood.

It is supplied as a pyrogen-free implant, in a sterile, single-use, pre-filled syringe, immediately ready for reconstitution.

Nanotherapeutics is focused on developing and marketing biodefence, infectious disease and influenza products worldwide.